Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in St. Stefan ob Stainz – page 23

426 clinical trials in St. Stefan ob Stainz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

St. Stefan ob Stainz at a glance
426
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

426 trials in St. Stefan ob Stainz

Open in trial search

Fabry's disease

Not recruiting

Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Agalsidase alfa
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Cholangiocarcinoma+7

Not recruiting

Study of bemarituzumab treatment for patients with solid tumors that have high levels of FGFR2b protein

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Long-term safety study of pelacarsen in patients with atherosclerotic cardiovascular disease who completed the Lp(a)HORIZON trial

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Colitis ulcerative

Not recruiting

Comparison of Risankizumab and Vedolizumab for Treatment of Moderate to Severe Ulcerative Colitis in Adults Who Have Not Received Targeted Therapies

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Risankizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Hepatitis D

Not recruiting

Clinical Trial for Patients with Chronic Hepatitis D: Comparing Brelovitug and Bulevirtide Treatments

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:BJT-778
  • Sponsor:Mirum Pharmaceuticals Inc.

Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:EYE103
  • Sponsor:Eyebiotech Limited

Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Durvalumab
  • Sponsor:Astrazeneca AB
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Metronidazole
  • Sponsor:Medical University Of Graz

Breast cancer+2

Not recruiting

Study on Denosumab to Prevent Breast Cancer in Women with BRCA1 Mutation

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Denosumab
  • Sponsor:ANZ Breast Cancer Trials Group Limited

Study on Insulin Aspart for Recovery from Low Blood Sugar in People with and without Type 2 Diabetes

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · Healthy volunteers
  • Substances:Insulin Aspart
  • Sponsor:Medical University Of Graz

Study Comparing Axatilimab to Best Available Therapy for Patients with Chronic Graft-Versus-Host Disease After Two or More Treatments

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in St. Stefan ob Stainz

What the registry says about research in the country

01 Hepatology Research

Innovative clinical trials focusing on non-alcoholic steatohepatitis (NASH), investigating advanced therapeutic approaches for liver disease management. The research examines the effectiveness of semaglutide in improving liver health and preventing disease progression.

  • Liver Histology Improvement
  • Fibrosis Management
  • Clinical Event Prevention

This two-part study aims to evaluate both immediate histological improvements and long-term clinical outcomes in patients with moderate to advanced liver fibrosis.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.